Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Inflammatory Bowel Diseases

Free Subscription 19.08.2024 3 Aliment Pharmacol Ther 1 Am J Gastroenterol 1 BMC Gastroenterol 1 Clin Gastroenterol Hepatol 2 Gut 4 Inflamm Bowel Dis 2 J Clin Gastroenterol 10 J Crohns Colitis

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Aliment Pharmacol Ther

1. SOLITANO V, Siegel CA, Korzenik JR, Maratt JK, et al
   Performance of bowel preparation quality scales in patients with Crohn's disease.
   Aliment Pharmacol Ther. 2024 Aug 11. doi: 10.1111/apt.18210.
   PubMed         Abstract available
   
   
2. PAL P, Mateen MA, Pooja K, Marri UK, et al
   Leveraging existing mid-end ultrasound machine for point-of-care intestinal ultrasound in low-resource settings: Prospective, real-world impact on clinical decision-making.
   Aliment Pharmacol Ther. 2024;60:633-647.
   PubMed         Abstract available
   
   
3. FERREIRO-IGLESIAS R, Porto Silva S, Marin S, Casanova MJ, et al
   Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registry.
   Aliment Pharmacol Ther. 2024;60:604-612.
   PubMed         Abstract available
   
   

   
   Am J Gastroenterol

4. AHMED NS, Krawchuk S, Buhler KA, Solitano V, et al
   US National Estimates of Contemporary Mortality Rates in Patients with Ulcerative Colitis Undergoing Colectomy.
   Am J Gastroenterol. 2024 Aug 14. doi: 10.14309/ajg.0000000000003031.
   PubMed         Abstract available
   
   

   
   BMC Gastroenterol

5. PASCUAL-MATO M, Garate G, Gonzalez-Quintanilla V, Castro B, et al
   Unravelling the role of beta-CGRP in inflammatory bowel disease and its potential role in gastrointestinal homeostasis.
   BMC Gastroenterol. 2024;24:262.
   PubMed         Abstract available
   
   

   
   Clin Gastroenterol Hepatol

6. HANNA LN, Anandabaskaran S, Iqbal N, Geldof J, et al
   Perianal fistulising Crohn's disease: utilising the TOpClass classification in clinical practice to provide targeted individualised care.
   Clin Gastroenterol Hepatol. 2024 Aug 10:S1542-3565(24)00692.
   PubMed         Abstract available
   
   

   
   Gut

7. PIERRE N, Huynh-Thu VA, Baiwir D, Mazzucchelli G, et al
   External validation of serum biomarkers predicting short-term and mid/long-term relapse in patients with Crohn's disease stopping infliximab.
   Gut. 2024 Aug 12:gutjnl-2024-332648. doi: 10.1136/gutjnl-2024-332648.
   PubMed         Abstract available
   
   
8. JACOBS JP, Spencer EA, Helmus DS, Yang JC, et al
   Age-related patterns of microbial dysbiosis in multiplex inflammatory bowel disease families.
   Gut. 2024 Aug 9:gutjnl-2024-332475. doi: 10.1136/gutjnl-2024-332475.
   PubMed         Abstract available
   
   

   
   Inflamm Bowel Dis

9. GISBERT JP, Schreiber S, Siegel CA, Magro F, et al
   Benefit-Risk Trade-offs and Patient Preferences for Therapy Selection in Ulcerative Colitis: a Multicountry Preference Study.
   Inflamm Bowel Dis. 2024 Aug 10:izae162. doi: 10.1093.
   PubMed         Abstract available
   
   
10. QIU Y, Hu S, Chao K, Huang L, et al
    Developing a Machine-Learning Prediction Model for Infliximab Response in Crohn's Disease: Integrating Clinical Characteristics and Longitudinal Laboratory Trends.
    Inflamm Bowel Dis. 2024 Aug 10:izae176. doi: 10.1093.
    PubMed         Abstract available
    
    
11. SHEHAB M, Hassan A, Alrashed F, Abbas A, et al
    Comparative Efficacy of Biologics and Small Molecule Therapies in Improving Patient-Reported Outcomes in Ulcerative Colitis: Systematic Review and Network Meta-Analysis.
    Inflamm Bowel Dis. 2024 Aug 13:izae163. doi: 10.1093.
    PubMed         Abstract available
    
    
12. MALHAM M, Vestergaard MV, Bataillon T, Villesen P, et al
    The Composition of the Fecal and Mucosa-adherent Microbiota Varies Based on Age and Disease Activity in Ulcerative Colitis.
    Inflamm Bowel Dis. 2024 Aug 16:izae179. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Clin Gastroenterol

13. GHUSN W, Mourad FH, Francis FF, Pasha S, et al
    The Use of Immunomodulators, Biologic Therapies, and Small Molecules in Patients With Inflammatory Bowel Disease and Solid Organ Transplant.
    J Clin Gastroenterol. 2024 Aug 14. doi: 10.1097/MCG.0000000000002049.
    PubMed         Abstract available
    
    
14. MAHMUD O, Fatimi AS, Mahar MU, Jahangir A, et al
    Efficacy and Safety of Sphingosine 1-Phosphate Receptor Modulators for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    J Clin Gastroenterol. 2024;58:753-763.
    PubMed         Abstract available
    
    

    
    J Crohns Colitis

15. HODGES P, Adeniyi O, Devani S, Nwoko C, et al
    Emerging patterns of inflammatory bowel disease in sub-Saharan Africa: 175 cases from an IBD network.
    J Crohns Colitis. 2024 Aug 14:jjae126. doi: 10.1093.
    PubMed         Abstract available
    
    
16. JANGI S, Zhao N, Hsia K, Park YS, et al
    Specific bacterial co-abundance groups are associated with inflammatory status in patients with ulcerative colitis.
    J Crohns Colitis. 2024 Aug 10:jjae125. doi: 10.1093.
    PubMed         Abstract available
    
    
17. BRODERSEN JB, Kjeldsen J, Juel MA, Knudsen T, et al
    Changes in endoscopic activity and classification of lesions with panenteric capsule endoscopy in patients treated for Crohn's disease - a prospective blinded comparison with ileocolonoscopy, faecal calprotectin and C-reactive protein.
    J Crohns Colitis. 2024 Aug 10:jjae124. doi: 10.1093.
    PubMed         Abstract available
    
    
18. DRAGONI G, Ke BJ, Picariello L, Abdurahiman S, et al
    The Impact of PAD4-dependent Neutrophil Extracellular Trap Formation on the Early Development of Intestinal Fibrosis in Crohn's Disease.
    J Crohns Colitis. 2024 Aug 10:jjae121. doi: 10.1093.
    PubMed         Abstract available
    
    
19. VERSTOCKT B
    Epigenetic Fingerprints in IBD: From Methylation Patterns to Clinical Implications.
    J Crohns Colitis. 2024;18:1175-1176.
    PubMed        
    
    
20. PEYRIN-BIROULET L, Dubinsky MC, Sands BE, Panes J, et al
    Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical Programme.
    J Crohns Colitis. 2024;18:1270-1282.
    PubMed         Abstract available
    
    
21. TANWAR H, Gnanasekaran JM, Allison D, Chuang LS, et al
    Unravelling the Oral-Gut Axis: Interconnection Between Periodontitis and Inflammatory Bowel Disease, Current Challenges, and Future Perspective.
    J Crohns Colitis. 2024;18:1319-1341.
    PubMed         Abstract available
    
    
22. ATIA O, Bryder N, Mendelovici A, Ledderman N, et al
    The Epidemiology of Inflammatory Bowel Diseases During the COVID-19 Pandemic: Comparison of Two Nationwide Cohorts.
    J Crohns Colitis. 2024;18:1241-1249.
    PubMed         Abstract available
    
    
23. FANTINI MC, Fiorino G, Colli A, Laharie D, et al
    Pragmatic Trial Design to Compare Real-world Effectiveness of Different Treatments for Inflammatory Bowel Diseases: The PRACTICE-IBD European Consensus.
    J Crohns Colitis. 2024;18:1222-1231.
    PubMed         Abstract available
    
    
24. GELDOF J, Truyens M, Hanssens M, Van Gucht E, et al
    Prophylactic Versus Endoscopy-driven Treatment of Crohn's Postoperative Recurrence: A Retrospective, Multicentric, European Study [PORCSE Study].
    J Crohns Colitis. 2024;18:1202-1214.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge.